Navigation Links
PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
Date:7/26/2013

LONDON and CAMBRIDGE, England, July 26, 2013 /PRNewswire/ --

PolyTherics receives new investment to accelerate growth

PolyTherics Limited ("PolyTherics") announces that it has merged with Antitope Limited ("Antitope"), the leading provider of antibody engineering and immunogenicity screening services, to create an enlarged group with an extensive suite of services and technologies to enable the development of better biopharmaceuticals.

PolyTherics is issuing new shares up to an aggregate value of £13.5 million to fund the merger with Antitope and to provide working capital for the enlarged group. Imperial Innovations (AIM: IVO) led the investment and brought in new investor Invesco Perpetual with further funds provided by Mercia Fund Management and Advantage Enterprise & Innovation Fund.

The enlarged PolyTherics group will leverage its combined portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development. The combined portfolio will include conjugation technologies to produce more stable and homogeneous antibody drug conjugates, technologies to optimise the pharmacokinetics of biologics, technologies for immunogenicity screening, technologies to re-engineer antibodies and proteins to reduce their immunogenicity, and cell line development technologies. The group has a strong client base in the biotechnology and pharmaceutical industry, including many of the world's top companies.

Dr John Burt will continue as CEO of PolyTherics and Antitope will operate as a wholly owned subsidiary of the PolyTherics group. Dr Matthew Baker will continue as Chief Scientific Officer for Antitope and the company will retain its base, management and operational structure at the Babraham Research Campus, near Cambridge.    

The ex
'/>"/>

SOURCE PolyTherics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shimadzu's New MALDI-7090 TOF-TOF Mass Spectrometer Combines High Throughput, High Resolution and High Energy for the Ultimate in Tandem MS Capabilities
2. FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice
3. Fantastic flash memory combines graphene and molybdenite
4. Motus Brings a Whole New Dimension to the NFL Combine Training Program at IMG Academy
5. New Informatics and Bioimaging Center combines resources, expertise from UMD, UMB
6. GDS International Combines Top Healthcare Executives in the United States for its 10th Anniversary NG Healthcare Summit in May
7. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
8. NYSCF scientists create personalized bone substitutes from skin cells
9. American Management Association Teams With Biogen Idec To Create Life Skills Workshops For People Living With Hemophilia
10. Data Spectacles Create Rosy Tint
11. Leading Biotoxin & Mold Illness Authority Creates Certification Process for Treatment Protocol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Stent retriever thrombectomy, an ... in the brain reduced disability after stroke, according ... MD, President of the Society of Vascular and ... a giant step forward that will change the ... patients," said Jovin, who is associate professor of ...
(Date:4/20/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the ... commercializing proven cancer therapies in new orphan drug ... 106th Annual Meeting of the American Association ... the potential for its lead product candidate ...
(Date:4/20/2015)... and Champaign, IL (PRWEB) April 20, 2015 ... the establishment of its 12th clinical research site: PMG ... Research has assumed operation of the clinical research department ... PMG’s footprint outside the Southeast to a second region ... a 150 multi-specialty physician practice enhances PMG’s access to ...
(Date:4/20/2015)... 20, 2015 Orthobiologics are substances ... injuries. The orthobiologics market is a rewarding market, which ... The global orthobiologics market report defines and segments the ... global orthobiologics market was valued at $5,712.4 million in ... 2019, at a CAGR of 6.7% from 2014 to ...
Breaking Biology Technology:SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) invites ... of the company,s 2008 investor meeting. The,corporate presentation ... Time on Thursday, March 13, 2008. The meeting ... of Jazz Pharmaceuticals, senior management team will provide ...
... Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") ... December 31, 2007., "2007 was our most ... the Company,s clinical trial program for REOLYSIN(R) with,Phase ... expanded and,initiated," said Dr. Brad Thompson, President and ...
... 6 Pathway Medical Technologies,which is developing innovative medical ... Buckman has been named as the new,Chairman of the ... been,acting Board Chairman since late 2006., "We are ... He brings,an extensive range of industry experience to the ...
Cached Biology Technology:Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 2Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 3Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 4Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 5Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 6Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 7Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 8Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 9Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors 2
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... antitumor drug could, in theory, shorten patients, long-term survival, comes ... suggests a potentially better option. The study appears in the ... (online April 27). Many cancer treatments work ... growing tumors. Agents that block a vessel-promoting factor called VEGF ...
... Philip E. Bourne, a computational biologist and professor with ... with the 2009 Benjamin Franklin Award this week in ... the free and open dissemination of science and scientific ... April 28, at the annual meeting of the Bioinformatics ...
... international agencies, including the director of the U.S. ... of cooperation that could reduce the number of ... The agreement between the United States, Canada, Japan ... scientific recommendations on alternative toxicity testing methods that ...
Cached Biology News:A longer lasting tumor blocker 2Open access advocate Philip E. Bourne to receive 2009 Benjamin Franklin Award 2Open access advocate Philip E. Bourne to receive 2009 Benjamin Franklin Award 3Countries unite to reduce animal use in product toxicity testing worldwide 2Countries unite to reduce animal use in product toxicity testing worldwide 3
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Inquire...
... Isoaspartate Detection Kit is intended for quantitative ... and peptides, which can result from the ... of aspartic acid residues during storage or ... on the monitoring of charge differences for ...
...
Biology Products: